« Back
Home /
Avitinib maleate

Avitinib maleate

Manufacturer	TargetMol
Category	Oncology Neuroscience Neural Signaling Reagents & Chemicals Molecules By Organ Bladder Cancer
Type	Molecules
Specific against	other
Amount	10mM*1mL(inDMSO)
Item no.	TMO-T3721-10mM
Targets	EGFR
CASRN	1557268-88-8
eClass 6.1	32169090
eClass 9.0	32169090
Available
Bioactivity	Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
MolWt	603, 61
Pathways	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
Receptor	EGFR

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10mM*1mL(inDMSO)

available

Delivery expected until 7/26/2024

Express Delivery: Save 3 days

Compare

Add to wishlist

Recommend by mail